Cargando…
Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial
Cerebral small vessel disease—a major cause of stroke and dementia—is associated with cerebrovascular dysfunction. We investigated whether short-term isosorbide mononitrate (ISMN) and cilostazol, alone or in combination, improved magnetic resonance imaging–measured cerebrovascular function in patien...
Autores principales: | Blair, Gordon W., Janssen, Esther, Stringer, Michael S., Thrippleton, Michael J., Chappell, Francesca, Shi, Yulu, Hamilton, Iona, Flaherty, Katie, Appleton, Jason P., Doubal, Fergus N., Bath, Philip M., Wardlaw, Joanna M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700302/ https://www.ncbi.nlm.nih.gov/pubmed/34847709 http://dx.doi.org/10.1161/STROKEAHA.121.034866 |
Ejemplares similares
-
Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial
por: Blair, Gordon W., et al.
Publicado: (2019) -
Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial
por: Appleton, Jason P., et al.
Publicado: (2019) -
Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease: baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
por: Bath, Philip M, et al.
Publicado: (2022) -
Isosorbide Mononitrate and Cilostazol Treatment in Patients With Symptomatic Cerebral Small Vessel Disease: The Lacunar Intervention Trial-2 (LACI-2) Randomized Clinical Trial
por: Wardlaw, Joanna M., et al.
Publicado: (2023) -
Correction: Cilostazol and isosorbide mononitrate for the prevention of progression of : baseline data and statistical analysis plan for the Lacunar Intervention Trial-2 (LACI-2) (ISRCTN14911850)
Publicado: (2022)